Form 4: Sutro Biopharma Exec Reports Equity Changes Post-Split
Insider Transaction Report
Sutro Biopharma's Chief Administrative Officer and General Counsel, David Pauling, reported recent equity transactions including RSU settlements and new grants, all adjusted for a 1-for-10 reverse stock split.
Summary
- David Pauling, Chief Administrative Officer and General Counsel of Sutro Biopharma, Inc. (STRO), reported changes in his beneficial ownership of company securities.
- Transactions occurred on March 1 and March 2, 2026, and include the acquisition of common stock from the settlement of Restricted Stock Units (RSUs) and the disposition of shares for tax withholding.
- On March 1, 2026, Pauling acquired 500 shares and 842 shares of common stock from RSU settlements, and disposed of 551 shares at $20.47 for tax obligations.
- On March 2, 2026, Pauling acquired 2,356 shares of common stock from RSU settlements, and disposed of 970 shares at $20.55 for tax obligations.
- Pauling also received new grants of 4,200 Restricted Stock Units (RSUs) and 33,600 stock options on March 2, 2026.
- All reported amounts, including dollar values, have been adjusted to reflect a 1-for-10 reverse stock split that became effective on December 3, 2025.
- Following these transactions, Pauling directly beneficially owns 9,350 shares of common stock, 4,200 RSUs, and 33,600 stock options.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting ongoing executive compensation through equity grants, which aligns management's interests with shareholders. The transactions are routine for an executive receiving equity awards.
Positives
- David Pauling received new grants of 4,200 Restricted Stock Units (RSUs) and 33,600 stock options, aligning his interests with long-term shareholder value.
- The vesting of RSUs and grant of new equity awards demonstrate continued compensation and retention of a key executive.
Negatives
- A total of 1,521 shares of common stock were disposed of (551 shares at $20.47 and 970 shares at $20.55) to satisfy income tax withholding obligations related to RSU settlements, which is a routine but non-discretionary reduction in direct share ownership.
Future Outlook
The filing indicates future vesting schedules for newly granted Restricted Stock Units and stock options, extending through March 2030 for RSUs and March 2036 for stock options, contingent on continued service. This suggests a long-term incentive structure for the executive.
Industry Context
StockSavvy.ai notes that routine insider transaction reports like this Form 4 are common in the biotechnology industry, where equity compensation, including RSUs and stock options, is a standard practice to attract and retain key talent. The reverse stock split, while a corporate action, is not directly indicative of broader industry trends but rather a company-specific decision often aimed at meeting listing requirements or improving stock perception.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Capital Structure Adjustment | The Issuer's Common Stock underwent a 1-for-10 reverse stock split, effective December 3, 2025, as approved by stockholders and filed with the Delaware Secretary of State. | 2025-12-03 | The reverse stock split reduces the number of outstanding shares and proportionally increases the share price, potentially impacting market perception and meeting exchange listing requirements. All equity compensation figures have been adjusted accordingly. |
Stakeholder Impact
- Shareholders: The grant of new RSUs and stock options to a key executive aligns management's incentives with shareholder value creation. The reverse stock split impacts the per-share value and number of shares held by existing shareholders, but not their total equity value.
- Employees: The equity compensation structure for executives sets a precedent for employee incentive programs, potentially impacting morale and retention.
Next Steps
- Continued vesting of 4,200 RSUs, with the first tranche vesting on March 1, 2027.
- Continued monthly vesting of 33,600 stock options, with the first tranche vesting on April 1, 2026.
Key Dates
| Date | Description |
|---|---|
| 2024-03-01 | First tranche vesting date for 500 RSUs. |
| 2025-03-01 | First tranche vesting date for 842 RSUs. |
| 2025-12-02 | Certificate of Amendment for Reverse Stock Split filed with Delaware Secretary of State. |
| 2025-12-03 | Effective date of 1-for-10 reverse stock split. |
| 2026-03-01 | Transaction date for RSU settlements and tax withholding; First tranche vesting date for 2,356 RSUs. |
| 2026-03-02 | Transaction date for RSU settlements, tax withholding, and new RSU and stock option grants. |
| 2026-03-03 | Signature date of the reporting person. |
| 2026-04-01 | First tranche vesting date for 33,600 stock options. |
| 2027-03-01 | Expiration date for 500 RSUs; First tranche vesting date for 4,200 RSUs. |
| 2028-03-01 | Expiration date for 842 RSUs. |
| 2029-03-02 | Expiration date for 2,356 RSUs. |
| 2030-03-01 | Expiration date for 4,200 RSUs. |
| 2036-03-02 | Expiration date for 33,600 stock options. |
Keywords
Sutro Biopharma, STRO, SEC Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Stock Options, Reverse Stock Split, David Pauling, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.